- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05068011
Differentiel mål multiplekset rygmarvsstimulering (DETECT)
Differentiel mål multiplekset rygmarvsstimulering: en multicenter kohorteundersøgelse
Evaluation of the effectiveness of differential target multiplexed spinal cord stimulation for treatment of chronic back and leg pain. Additionally, a subgroup analysis will be performed to evaluate potential differences between paddle/surgical leads versus percutaneous leads.
Studieoversigt
Status
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiesteder
-
-
-
Antwerp, Belgien
- ZNA
-
Bruges, Belgien
- AZ Sint-Jan Brugge-Oostende
-
Bruges, Belgien
- AZ Sint-Lucas Brugge
-
Hasselt, Belgien
- Jessa Ziekenhuis
-
Kortrijk, Belgien
- AZ Groeninge
-
Leuven, Belgien
- UZ Leuven
-
Lier, Belgien
- Heilig Hart Ziekenhuis Lier
-
Liège, Belgien
- Centre Hospitalier Régional (CHR) de la Citadelle
-
Mechelen, Belgien
- AZ Sint-Maarten
-
Roeselare, Belgien
- AZ Delta
-
Sint-Niklaas, Belgien
- Vitaz
-
Turnhout, Belgien
- AZ Turnhout
-
Wilrijk, Belgien
- GZA
-
-
Brussels Capital
-
Jette, Brussels Capital, Belgien, 1090
- Universitair Ziekenhuis Brussel
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients with chronic back and leg pain due to Failed Back Surgery Syndrome (FBSS)/Persistent Spinal Pain Syndrome type 2 (PSPS-T2), who will receive treatment with differential target multiplexed (DTM) SCS.
Beskrivelse
Inclusion Criteria:
- Patients with severe chronic pain (> 5 on numeric rating scale, NRS) for at least 6 months due to FBSS (PSPS T2) and suitable for treatment with DTM SCS according to the treating physician
- Age > 18 years
- Patient has been informed of the study procedures and has given written informed consent
- Patient willing to comply with study protocol including attending the study visits
Exclusion Criteria:
- Expected inability of the patient to receive or properly operate the spinal cord stimulation system
- History of coagulation disorder, lupus erythematosus, diabetic neuropathy, rheumatoid arthritis, or morbus Bechterew
- Active malignancy
- Addiction to drugs, alcohol (>5 units per day) and/or medication
- Evidence of an active disruptive psychiatric disorder or other known condition that may impact perception of pain, compliance to the intervention, and/or ability to evaluate treatment outcome as determined by investigator
- Immune deficiency (e.g. HIV positive, immunosuppressive treatment)
- Life expectancy < 1 year
- Local infection or any other skin disorder at site of incision
- Pregnancy
- Other implanted active medical device
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Spinal cord stimulation
Patients will receive differential target multiplexed spinal cord stimulation |
differential target multiplexed stimulation |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall pain intensity with Visual Analogue Scale (VAS)
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Overall pain, defined as a combination of back and leg pain, but not pain from other body parts, measured with the VAS (100mm) |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Intensitet af rygsmerter med Visual Analogue Scale (VAS)
Tidsramme: Ændringen mellem baseline-screeningen og evalueringen 1 måned efter DTM-stimulering, 6 måneder og 12 måneder
|
Ændringen mellem baseline-screeningen og evalueringen 1 måned efter DTM-stimulering, 6 måneder og 12 måneder
|
|
|
Bensmerteintensitet med Visual Analogue Scale (VAS)
Tidsramme: Ændringen mellem baseline-screeningen og evalueringen 1 måned efter DTM-stimulering, 6 måneder og 12 måneder
|
Ændringen mellem baseline-screeningen og evalueringen 1 måned efter DTM-stimulering, 6 måneder og 12 måneder
|
|
|
Klinisk holistisk responderstatus
Tidsramme: Ændringen mellem baseline-screeningen og evalueringen 1 måned efter DTM-stimulering, 6 måneder og 12 måneder
|
Ændringen mellem baseline-screeningen og evalueringen 1 måned efter DTM-stimulering, 6 måneder og 12 måneder
|
|
|
Andel af vellykkede DTM-forsøg.
Tidsramme: Evalueret efter endelig SCS-implantation
|
Evalueret efter endelig SCS-implantation
|
|
|
Batteriforbrug
Tidsramme: Tilmelding ved 1 måned, 6 måneder og 12 måneder af DTM SCS
|
Tilmelding ved 1 måned, 6 måneder og 12 måneder af DTM SCS
|
|
|
Udbredelse af tekniske problemer med hensyn til DTM SCS programmering
Tidsramme: Gennem hele studietiden
|
Gennem hele studietiden
|
|
|
DTM SCS-stimuleringsparametre
Tidsramme: Tilmelding ved 1 måned, 6 måneder og 12 måneder af DTM SCS
|
Tilmelding ved 1 måned, 6 måneder og 12 måneder af DTM SCS
|
|
|
Pain medication use
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Open question regarding the dosage, frequency and type of pain medication |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Functional disability
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The functional disabilities will be assessed with the Oswestry Disability Index (ODI) |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Health related quality of life
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Health related quality of life, evaluated with the EuroQol with five dimensions and 5 levels |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Patient global impression of change
Tidsramme: Evaluated at 1 month, 6 months and 12 months of DTM SCS.
|
Patients will be asked to quantify the impression of change after treatment using the Patient Global Impression of Change scale (PGIC). |
Evaluated at 1 month, 6 months and 12 months of DTM SCS.
|
|
Patients' individual competencies for self-management
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Patient activation measure-13 (PAM) is a 13-item instrument which assesses self-reported behaviour, knowledge, and confidence for self-management of one's health. |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Work status
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Work status is evaluated with a self-designed questionnaire |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Pain catastrophizing
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The Pain Catastrophizing Scale (PCS) will be used to measure the level of pain catastrophizing |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Symptoms of central sensitisation.
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The Central Sensitization Inventory is used to measure symptoms of central sensitisation |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Anxiety and Depression.
Tidsramme: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The hospital Anxiety and Depression Scale (HADS) will measure symptoms of anxiety and depression |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Healthcare utilisation.
Tidsramme: The change between implantation and evaluation at 1 month, 6 months and 12 months of DTM SCS
|
Postoperative healthcare expenditure will be investigated by self-reporting methods. |
The change between implantation and evaluation at 1 month, 6 months and 12 months of DTM SCS
|
|
Time spent in body postures
Tidsramme: The data will be extracted from SCS implantation up to 1 month of SCS, from 1 month of SCS up to 6 months and from 6 months up to 12 months
|
Based on the AdaptiveStim technology, the time spent in body postures can be recorded. |
The data will be extracted from SCS implantation up to 1 month of SCS, from 1 month of SCS up to 6 months and from 6 months up to 12 months
|
|
(Serious) adverse events
Tidsramme: Throughout study period
|
Systematically recording all adverse events |
Throughout study period
|
|
Patient expectations concerning SCS
Tidsramme: Evaluated at baseline visit
|
Self-constructed open question to evaluate patient expectations about SCS |
Evaluated at baseline visit
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- DETECT
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .